Navigation Links
D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
Date:3/4/2008

REHOVOT, Israel, March 4 /PRNewswire/ -- D-Pharm announced today that it has held its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the forthcoming IND submission for DP-b99, a novel drug to aid recovery following acute stroke. The Pre-IND meeting focused on the proposed plans for the Phase III clinical program and the discussion included clinical trials to date, preclinical pharmacology, toxicology data and the FDA requirements and suggestions for the IND submission. DP-b99 is a unique drug protecting brain cells in stroke patients, discovered and developed by D-Pharm.

Alex Kozak, PhD, President and CEO of D-Pharm, said "The positive and constructive feed-back we've received from the FDA is most encouraging. With a number of uncertainties in the developmental program removed we may now follow a clear path towards an IND application for a pivotal Phase III study towards the end of this year. This is good news for D-Pharm and for stroke patients."

Most recently, D-Pharm successfully completed a Phase IIb trial for DP-b99 in 150 ischemic stroke patients. Results from this study will be published shortly in the peer reviewed journal, Stroke. DP-b99 statistically significantly increased by two-fold the percentage of patients that completely recovered from ischemic stroke. In addition, DP-b99 has at least a 9hr therapeutic window and may be safely administered in this patient population.

D-Pharm has commenced preparations for the pivotal Phase III trial, including manufacturing of the drug, certain customary studies and IND submission. The Phase III trial is expected to commence in 2009 and to recruit about 750 moderately severe acute stroke patients in North America, Europe and Asia. D-Pharm will be seeking a suitable CRO for the next study with DP-b99. Interested CROs can find more details by following this link:

http://www.dpharm.com/docs/reports/Call_for_proposals_for_DP-b99_Ph_III _s

tudy.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About Stroke

Every year approximately 750,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the mean lifetime cost resulting from an ischemic stroke is estimated at $140,000 per patient. Other than tissue plasminogen activator (tPA), which must be administered 3 hours after stroke, there are no FDA approved medicines for this indication.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products, DP-b99 and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and migraine prophylaxis, currently in Phase II development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer.

For further information please contact:

Tami Horovitz, PhD.

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com


'/>"/>
SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Plurality Completes R&D of its HAL-256 Multicore Processor
2. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
3. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
4. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
5. Cardium Completes $5.3 Million Registered Direct Offering
6. WuXi PharmaTech Completes Acquisition of AppTec
7. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
8. Healionics Corporation Completes Series A Financing
9. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
10. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
11. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Bethesda, MD (PRWEB) , ... January 18, 2017 ... ... for the National Institutes of Health (NIH) to update its Data Sharing Policy. ... a “scoreable” element of grant applications subject to the existing policy. AMIA recommended ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical ... spectrum of drug and device development, and Prism Clinical Research , a ... today announced Verified Clinical Trials (VCT) has been selected by both ...
(Date:1/19/2017)... N.Y. , Jan. 18, 2017 Acupath ... services, announces the formation of an Executive Committee that ... and beyond. John Cucci , a ... promoted from Director of Business Development to Chief ... 2015, Mr. Cucci served in senior sales leadership roles ...
(Date:1/18/2017)... , January 18, 2017 According to a new ... Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and ... expected to reach USD 739.9 Million by 2021 from USD 557.1 Million in ... Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/11/2017)... 11, 2017  Michael Johnson, co-founder of Visikol Inc. a company ... has been named to the elite "Forbes 30 Under 30" list ... 600 people in 20 fields nationwide to be recognized as a ... applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):